BiPar Sciences to Present At the 11th Annual BIO CEO & Investor Conference in New York City

Presentation Scheduled for 11:30 am EST On Monday, February 9, 2009

| Source: BiPar Sciences

BRISBANE, Calif., Feb. 3, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that President and Chief Executive Officer Hoyoung Huh, M.D., Ph.D., will present information on BiPar's development programs and product pipeline, including the latest information on the company's lead product candidate, BSI-201 which is in randomized Phase 2 clinical trials in triple negative breast cancer, at the 2009 BIO CEO & Investor Conference 2009 located in New York City, NY.

Dr. Huh will present on February 9th at 11:30 am EST at the Waldorf-Astoria Hotel located at 301 Park Avenue in New York City.

About BiPar Sciences and BSI-201

BiPar Sciences, Inc. is a clinical-stage biopharmaceutical company focused on DNA repair using Poly ADP-Ribose Polymerase (PARP) inhibitors. PARP inhibitors represent a new, targeted approach to treating many types of cancers. By preventing cancer cells from repairing their own DNA, PARP inhibitors ultimately cause cancer cell death. The company's lead product candidate is BSI-201, a potential first-in-class and best-in-class PARP inhibitor currently being studied in Phase 2 testing for metastatic triple negative breast cancer, ovarian cancer and other malignancies. The company also has two additional compounds in pre-clinical development, BSI-401, a follow-on PARP inhibitor candidate being investigated as an oral therapy for pancreatic cancer and BSI-302, a novel anti-tubulin therapy. BiPar Sciences is privately held with headquarters in Brisbane, California. For more information, please visit

About Triple Negative Breast Cancer (TNBC)

When patients are diagnosed with breast cancer, their tumors are routinely tested for and classified based on the presence of estrogen, progesterone, and HER2 receptors. Commonly used breast cancer therapies, such as tamoxifen and Herceptin(r), target these receptors. However, up to 20 percent of all breast cancers are negative for all three receptors, thus giving rise to the term "triple negative breast cancer (TNBC)."

TNBC is a difficult-to-treat cancer subtype that does not have an approved standard-of-care and does not respond to current hormone-based and targeted therapies. TNBC is a very aggressive cancer, with higher rates of metastases and poorer survival rates than other breast cancer subtypes. The prevalence of the TNBC subtype is higher in younger and African-American women.

Continuum Health Communications
Media Contact:
Terri Clevenger